# aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
Canonical URL: https://biopharmsignal.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidosis-following-fda-type-c-meeting
Ticker: ATYR
Company: aTyr Pharma
Source: aTyr Pharma
Published: 2026-05-11 20:01 EST
Original Source URL: https://investors.atyrpharma.com
## Summary

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary

## Article Body
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary
## Recent Company News
- 2026-05-15 12:00 EST — [aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-05-13 20:01 EST — [aTyr Pharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ATYR/atyr-pharma-to-participate-in-upcoming-investor-conferences) — Source: aTyr Pharma
- 2026-05-11 20:01 EST — [aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting](https://biopharmsignal.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidosis-following-fda-type-c-meeting) — Source: aTyr Pharma
- 2026-03-05 21:01 EST — [aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-02-20 21:01 EST — [aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: aTyr Pharma
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)